On May 18, 2016 Oryzon Genomics (ISIN Code: ES0167733015), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in oncology and neurodegenerative diseases, reported that the 2-year R&D collaboration with Roche concerning ORY-1001, licensed to Roche in 2014, has been extended until March 2017 (Press release, , MAY 18, 2016, View Source [SID:1234512557]). Schedule your 30 min Free 1stOncology Demo! ORY-1001 (RG6016) is a highly potent and selective inhibitor of LSD1 currently in Phase I/IIA in acute leukemia patients. The license agreement by which the development and commercial rights to ORY- 1001 were granted to Roche, included a 2-year collaborative research program between Oryzon and Roche to further explore the potential of ORY-1001 in oncology and haematology. The program has delivered additional insight into the drug’s mechanism of action, provided support for its use in indications beyond acute leukemia and has expanded the toolbox for future and current clinical trials. Oryzon will continue to support the development of ORY-1001 through an extension of the collaborative research program that will run until March 2017 with the main goal to finalize the transfer of the newly generated technology and knowledge.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Carlos Buesa, Oryzon’s CEO, has declared: "This collaboration between Roche and Oryzon has been highly satisfactory and the success of the collaboration is reflected in four newly filed patent applications. We have been impressed by the experience of our partner and are convinced the results generated will strengthen the further clinical development of ORY-1001. "